who should avoid glp-1 medications Researchers find safe to continue before surgery in patients with diabetes and obesity (Medical Xpress) Comparing GLP‑1 Drugs With Other

Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs

Weight Loss and Obesity Treatment In addition to their role in managing type 2 diabetes, GLP-1 agonists have gained significant attention for their potential in promoting weight loss and treating obesity

It should be mentioned that some gliptins, like linagliptin and saxagliptin may be metabolized via the CYP3A4 or CYP3A4/5 pathways, and this could result in a diminished clearance of other drugs using the same pathways

The pathobiology of diabetic complications: a unifying mechanism

Kasagga A et al

Considerations for specific populations Despite the adherence improvement and convenience of GLP-1 patches, they may not be the best option for some people, including: Elderly patients usually have frail skin, making it challenging to apply and remove the transdermal patch